It was a pleasure to talk with Dr. Andrea R. Genazzani (International Society of Gynecological Endocrinology and European Society of Gynecology) to find out when, in whom and for how long hormone replacement therapy should be administered for bone loss prevention post-menopause. ‘Hormone Replacement Therapy in post-menopause for bone loss prevention: when, how and for […]

touchENDOCRINOLOGY were delighted to catch up with Dr. Andrea R. Genazzani (International Society of Gynecological Endocrinology and European Society of Gynecology) to discuss the health burden of osteoporosis in post-menopausal women and how HRT could be used as a prevention strategy. ‘Hormone Replacement Therapy in post-menopause for bone loss prevention: when, how and for how […]

touchENDOCRINOLOGY had the pleasure of talking with TOS President Prof Dan Bessesen (UCHealth, University of Colorado, Aurora, CO, USA) around this year’s ObesityWeek®, the key highlights and future Obesity Society activities to look forward to. Questions Could you tell us a little about ObesityWeek® and its key themes for 2022? (0:21) What do you expect […]

In Part 2, we speak with Prof. Arun Sanyal (Virginia Commonwealth University, Richmond, VA, USA) about the interim analysis from the ICONA trial (NCT04052516) which is designed to investigate icosabutate as a potential therapeutic approach to address liver- and cardiovascular-related morbidity and mortality in patients with NASH. His abstract entitled ‘Icosabutate, a novel structurally engineered […]

Obesity is a growing problem worldwide with extensive health and economic consequences, rendering interventions that encourage weight loss of great interest. Obesity is usually defined as a body mass index (BMI) of 30 kg/m2 or above, or 27.5 kg/m2 or above in Asian populations. Based on the health survey for England 2019, 28% of adults in England […]

McCune–Albright syndrome (MAS) is a genetic disorder first described by McCune1 and Albright2  in the 1930s as a triad of polyostotic fibrous dysplasia, café-au-lait spots, and precocious puberty (Figure 1). Since then, other hyperfunctioning endocrinopathies have been described in MAS, including hyperthyroidism, Cushing’s syndrome, hypophosphatemic osteomalacia, and acromegaly.3 Patients with MAS display mosaicism as the disease results […]

Catecholamine-secreting tumours that arise from chromaffin cells of the adrenal medulla and the sympathetic ganglia are respectively referred to as pheochromocytomas and paragangliomas. The term paraganglioma is also used for tumours derived from parasympathetic tissue in the head and neck, most of which do not produce catecholamines.1 The classic triad of symptoms in patients with […]

Diabetic polyneuropathy (DPN) is the most common microvascular complication of diabetes, affecting approximately 50% of all people with diabetes (type 1 diabetes [T1D] and type 2 diabetes [T2D]).1 DPN is a major cause of disability due to sensory loss, gait instability and fall‐related injuries,1–5 and is the strongest risk factor for diabetic foot ulceration and amputation.1–4 Up to […]